Transcriptomics analysis of the screened cell lines showed that mutations that lead to overactivation of BRAF can predict the loss of RIPK3 expression levels in cancer, despite many of the BRAFWT cell lines displaying low RIPK3 expression, consistent with its heterogeneous nature (Fig 4C, S4 and S5 Tables), similar to that of high AXL expression levels. The gene discussed is BRAF; the disease is cancer.